Obesity, a major risk factor for type 2 diabetes and cardiovascular diseases, is characterized by an abnormal expansion of adipose tissue. Herein, we investigated the potential of hyaluronic acid nanoparticles (HA-NPs) as therapeutics to treat obesity-related diseases by assessing the in vitro and in vivo effects of HA-NPs on adipogenesis and lipogenesis. Treatment of 3T3-L1 preadipocytes with HA-NPs resulted in a dose-dependent suppression of adipogenesis and lipid accumulation, and decreased the expression of key adipogenic and lipogenic regulators. However, these HA-NPs mediated effects were not observed in 3T3-L1 cells transfected with siRNAs against CD44, a major HA receptor. Further, HA-NP treatment of diet-induced obese (DIO) mice reduced the epididymal fat mass and suppressed the induction of adipogenic and lipogenic regulators, while these effects were attenuated in the CD44-null mice. Thus, our study provides a better understanding of how HA-NP modulates fat accumulation and presents a potential anti-obesity strategy targeting CD44.

肥胖是2型糖尿病和心血管疾病的主要危险因素，其特征是脂肪组织异常扩张。在此，我们通过评估所研究的透明质酸的纳米颗粒（HA-NPS）的电位作为治疗剂以治疗肥胖相关疾病的体外和体内HA-NPs对脂肪生成和脂肪生成的影响。用HA-NPs处理3T3-L1前脂肪细胞可导致剂量依赖性抑制脂肪生成和脂质蓄积，并降低关键的脂肪生成和脂肪生成调节剂的表达。但是，在用针对主要HA受体CD44的siRNA转染的3T3-L1细胞中未观察到这些HA-NPs介导的作用。此外，饮食诱导肥胖（DIO）小鼠的HA-NP治疗减少了附睾脂肪量并抑制了脂肪形成和脂肪形成调节剂的诱导，而这些作用在CD44无效的小鼠中减弱了。因此，我们的研究提供了对HA-NP如何调节脂肪积累的更好理解，并提出了针对CD44的潜在抗肥胖策略。